Pooled evidence from 2 randomized trials and 6 observational cohorts suggests posttransplant gilteritinib maintenance may ...

PARADIGM data suggest azacitidine plus venetoclax improves AML event-free survival vs 7+3 with less toxicity; survival looks ...

Recent years have brought a more targeted approach to treating acute myeloid leukemia (AML) based on accumulating knowledge about the genetic makeup of the heterogenous disease. “Over the past decade, ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the 45th subject has been enrolled in its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in ...

Key combination for the treatment of first-line AML Recent data from an ongoing study in first-line AML showed a 100% overall response rate (ORR) ...

Panelists discuss how fitness assessment has evolved beyond traditional age cutoffs to incorporate comprehensive geriatric assessments, frailty measures, and individualized evaluations, while ...

Moleculin Biotech ( (MBRX)) just unveiled an announcement. Moleculin Biotech has revealed promising findings showcasing Annamycin’s potential to combat acute myeloid leukemia (AML) resistant to ...

The study focuses on patients unlikely to benefit from azacitidine/venetoclax or showing early resistance. ・SLS009 showed ...

Actinium Pharmaceuticals is a late-stage biopharmaceutical company focused on developing radiotherapies for AML patients. The company's leading product candidate, Iomab-B, has shown promising results ...

Net loss in FY25 narrowed to $26.9 million from $30.9 million a year ago, with R&D costs falling to $16 million. ・Phase 3 ...

Acute Myeloid Leukemia is the most common acute leukemia in adults affecting 2-6 adults per 100,000k globally.​ -With relapse ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Moleculin Biotech ( (MBRX)) has ...